GlobeNewswire

Corvil Wins Best Time Synchronisation Solution at A-Team Group's RegTech Awards 2018

Dela

Corvil's UTC Traceability solution for MiFID and CAT compliance recognized for its innovation and value in accelerating customer compliance with emerging regulations

DUBLIN, Ireland, May 04, 2018 (GLOBE NEWSWIRE) -- Corvil continues to be recognized as the "gold-standard" for machine-time analytics, achieving the "Best Time Synchronisation Solution" award in the A-Team Group's RegTech Awards 2018, for its Coordinated Universal Time (UTC) Solution for MiFID and CAT Compliance.

Regulatory bodies have turned to time precision and integrity as a critical dependency for  providing transparency, auditability, and accountability for algorithmic business such as digital financial transactions, including electronic trading.   Under MiFID II and incoming Consolidated Audit Trail (CAT) rules, market participants must establish, demonstrate and maintain clock synchronization with a Coordinated Universal Time (UTC) source to a high degree of accuracy.  

Corvil's UTC Traceability solution watches over clock synchronization integrity to assure compliance and reduce regulatory tail risk.   Furthermore, it demonstrates the firm's ability to excel in agile innovation and build cost-effective solutions to extend its business and operational value to help customers respond to evolving regulatory regimes.

"We have long seen precision time-handling as the basis for establishing causality for forensics as well as accurate business transaction analysis, network and application performance management, and cyber-security," said Raymond Russell, Corvil's co-founder and CTO.   "Our core platform's handling of time, short time-scale analysis, and identification of clock synchronization status by message not only provide a key asset for current and future regulatory compliance, but is proving a minimum requirement for effective digital business, cyber surveillance, and AI Ops."

Corvil has a nearly 20-year history of shaping trading and algorithmic business technology through transforming network data into intelligence for execution performance, client intelligence and experience, regulatory compliance and cyber risk surveillance.  The firm's industry-leading precision in nanosecond time-stamping of every reportable event in a transaction's lifecycle goes well beyond current regulatory requirements. 

Providing a solution to likely address future tightening of clock synchronization and timestamping requirements, Corvil Analytics delivers a robust, long-term solution for customers.   This forward-looking capability, Corvil's de facto industry standard solution for trade performance monitoring, as well as automated daily and on-demand reporting for compliance and business teams are among the differentiators that have propelled Corvil's RegTech success.  Today, Corvil proudly counts almost every major stock exchange and global bank as a customer.

"We are pleased to congratulate Corvil on their prestigious RegTech Awards 2018 win," said Laurie McAughtry, Editor at A-Team Group.  "Our readership of senior trading technology executives clearly recognized Corvil's contributions to their operational, business, and compliance solutions in voting Corvil as the leading provider of Best Time Synchronisation Solution."

"We are delighted with the recognition of our UTC Traceability Solution from our peersMiFID II and CAT are significant not only to the world of finance but to the wider business landscape as they represent a new era of digital algorithmic and AI oversight through the lens of machine-time, - where faster and smarter machine technology operates autonomously at nanosecond speed," said David Murray, Chief Marketing and Business Development Officer at Corvil.  "Our expertise in this  new reality of time , puts us in a strong position to address future regulatory rules as well as apply our RegTech capabilities to other algorithmic and AI powered businesses."

Corvil's strong performance in empowering firms with insight into client and trader intelligence, market data quality, order and transaction performance as well as technology performance to optimize execution, continues to garner peer recognition.  In the past 12 months the firm achieved "Best Time-Stamping / Infrastructure Performance Monitoring" at Intelligent Trading Technology Awards 2017; "Best Financial Transaction Security Platform" in 2018 FinTech Breakthrough Awards while Institutional Investor recently named Corvil CEO, Donal Byrne, among world's top 25 Innovators in trading technology.

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn

Media Contact
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/b1fcbd60-7b75-44f0-b25d-40b32fb0c975




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum